Clinical trial Recruiting at 2 sites Phase 2 Interventional Ages 18 to 50

Using a medication to treat headaches after mild brain injuries in military and civilian patients

Official title: Treatment of Acute Post-Traumatic Headache With Erenumab 140 mg, Military Service Members and Civilians With Mild TBI: A Randomized, Double Blind, Placebo Controlled, Multicenter 12-week Duration Study Followed by a 4-week Open-Label Safety Extension

Run by Henry M. Jackson Foundation for the Advancement of Military Medicine · NCT05049057 · Data updated 2026-11-12

This study is testing if a new medication can help people with mild brain injuries and headaches feel better compared to a placebo.

More Mild Traumatic Brain Injury trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 50 Years
SexAll
Enrollment404 (estimated)
SponsorHenry M. Jackson Foundation for the Advancement of Military Medicine
Academic / other
Drugs / interventionserenumab
Locations4 sites (Fort Bragg, North Carolina and 3 other locations)
StatusRecruiting
StartedJuly 19, 2022
Main results expectedMay 19, 2026
Study endsMay 19, 2027
Registry record updatedFebruary 22, 2024
Trial IDNCT05049057 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are military service members and civilians aged 18 to 50 who have experienced mild traumatic brain injury and posttraumatic headache within the past week.

Probably not a fit

Patients with moderate or severe traumatic brain injuries or chronic headache disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and effectiveness of erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP), for treating acute posttraumatic headache (PTH) in individuals with mild traumatic brain injury (mTBI). It is a randomized, double-blind, placebo-controlled trial conducted at military treatment facilities across the United States. Participants will receive either erenumab or a placebo to determine the medication's impact on headache relief and overall safety. The study focuses on individuals who have experienced mTBI and PTH within the last week.

Why it matters

Potential benefit: If successful, this treatment could significantly alleviate headache symptoms in patients suffering from posttraumatic headaches following mild traumatic brain injuries.

How similar studies have gone: Other studies have shown promising results with CGRP inhibitors for migraine treatment, suggesting potential success for this novel application in posttraumatic headache.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Male or female ≥18 and ≤50 years of age
* mTBI from any cause including impact, rotational acceleration, blast, or a combination, has occurred within the prior 7 days
* PTH has occurred within the prior 7 days
* Able to provide informed consent
* Likely to stay in the same geographical area for the duration of study
* Has a personal health care provider for standard of care PTH and TBI, including education, diagnostic procedures including neuroimaging and treatment, as deemed clinically indicated by the health care provider

Exclusion Criteria:

* Sustained a moderate or severe TBI, rather than mTBI, indicated with at least 1 of the following associated with head injury:

  1. abnormal structural imaging
  2. loss of consciousness for \>30 minutes
  3. alteration of consciousness/mental state for \>24 hours 3. post-traumatic amnesia for \>1 day
* Participants with ongoing chronic migraine or other chronic daily headache disorders at the time of injury

Where it's running

  • Womack Army Medical Center - Fort Liberty
    Fort Bragg, North Carolina, United States
    Recruiting
  • William Beaumont Army Medical Center
    El Paso, Texas, United States
    Recruiting
  • University of Pittsburgh Concussion Research Laboratory
    Pittsburgh, Pennsylvania, United States
    Not yet recruiting
  • Madigan Army Medical Center
    Tacoma, Washington, United States
    Not yet recruiting

Study contacts

  • Principal investigator: David L Brody, MD, PhD — Uniformed Services University of the Health Sciences
  • Study coordinator: Amy Guthrie, RN
  • Email: amy.guthrie.ctr@usuhs.edu
  • Phone: 202-924-2729

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.